ECSP088454A - USE OF TRANSFER MODIFYING AGENTS MORE CHEMOTHERAPY OR RADIOTHERAPY AGAINST CANCER - Google Patents
USE OF TRANSFER MODIFYING AGENTS MORE CHEMOTHERAPY OR RADIOTHERAPY AGAINST CANCERInfo
- Publication number
- ECSP088454A ECSP088454A ECSP088454A ECSP088454A EC SP088454 A ECSP088454 A EC SP088454A EC SP088454 A ECSP088454 A EC SP088454A EC SP088454 A ECSP088454 A EC SP088454A
- Authority
- EC
- Ecuador
- Prior art keywords
- chemotherapy
- radiotherapy
- modifying agents
- transcriptome
- against cancer
- Prior art date
Links
- 238000002512 chemotherapy Methods 0.000 title abstract 3
- 238000001959 radiotherapy Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000007067 DNA methylation Effects 0.000 abstract 1
- 108010033040 Histones Proteins 0.000 abstract 1
- 229960002474 hydralazine Drugs 0.000 abstract 1
- 229940023568 magnesium valproate Drugs 0.000 abstract 1
- LKLLHOIUJVEAGU-UHFFFAOYSA-L magnesium;2-propylpentanoate Chemical compound [Mg+2].CCCC(C([O-])=O)CCC.CCCC(C([O-])=O)CCC LKLLHOIUJVEAGU-UHFFFAOYSA-L 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 239000003607 modifier Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se relaciona con el uso de agentes modificantes del transcriptoma con el objetivo de impedir a las células malignas realizar los cambios génicos necesarios para hacer frente al insulto celular y sobrevivir a la quimioterapia o radioterapia. Esta combinación de modificantes del transcriptoma serán agentes que inhiban la maquinaria de metilación del DNA más una sustancia que impida las modificaciones post-transduccionales de las histonas. Se presenta un kit de tratamiento que consiste en la administración de una dosis efectiva de hidralazina más valproato de magnesio para coadyuvar con la radioterapia o quimioterapia en el tratamiento de pacientes con cáncer.The present invention relates to the use of transcriptome modifying agents in order to prevent malignant cells from making the necessary gene changes to cope with cell insult and survive chemotherapy or radiotherapy. This combination of transcriptome modifiers will be agents that inhibit DNA methylation machinery plus a substance that prevents post-transduction histone modifications. A treatment kit is presented consisting of the administration of an effective dose of hydralazine plus magnesium valproate to help with radiotherapy or chemotherapy in the treatment of cancer patients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP088454 ECSP088454A (en) | 2008-05-16 | 2008-05-16 | USE OF TRANSFER MODIFYING AGENTS MORE CHEMOTHERAPY OR RADIOTHERAPY AGAINST CANCER |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP088454 ECSP088454A (en) | 2008-05-16 | 2008-05-16 | USE OF TRANSFER MODIFYING AGENTS MORE CHEMOTHERAPY OR RADIOTHERAPY AGAINST CANCER |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP088454A true ECSP088454A (en) | 2008-08-29 |
Family
ID=40434934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP088454 ECSP088454A (en) | 2008-05-16 | 2008-05-16 | USE OF TRANSFER MODIFYING AGENTS MORE CHEMOTHERAPY OR RADIOTHERAPY AGAINST CANCER |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP088454A (en) |
-
2008
- 2008-05-16 EC ECSP088454 patent/ECSP088454A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202106265B (en) | Compositions and methods for inhibiting gene expression of lpa | |
| AR073563A1 (en) | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND RELATED STATES | |
| UY31543A1 (en) | SYSTEM OF ADMINISTRATION OF RNAI OF INTERFERENCE AND USES OF THE SAME | |
| MX2017013321A (en) | Rna containing composition for treatment of tumor diseases. | |
| CY1121838T1 (en) | COMPOSITIONS COMPRISING HAPHIUM(IV) OXIDE OR RHENIUM(IV) OXIDE NANOPARTICLES IN COMBINATION WITH IONIZING RADIATION FOR THE TREATMENT OF CANCER | |
| BR112015029386A8 (en) | use of eribulin and lenvatinib as combination therapy, pharmaceutical composition comprising them and kit | |
| MX375836B (en) | COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE ALPHA-1 ANTITRYPSIN GENE. | |
| MX2019014800A (en) | RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE. | |
| MX2017014641A (en) | Compositions and methods for inhibiting gene expression of hif2alpha. | |
| UY32546A (en) | COMPOSITIONS AND METHODS TO TREAT CANCER | |
| NI201500063A (en) | CANCER TREATMENT WITH POMALIDOMIDE IN AN INDIVIDUAL WITH KIDNEY DAMAGE | |
| ECSP14013195A (en) | CATHETER, IN PARTICULAR PERMANENT CATHETER FOR THE TREATMENT OF DYSFUNCTIONS AND / OR DISEASES OF THE BLADDER AND / OR THE PROSTATE. | |
| PE20200295A1 (en) | MITOOCETOSCINES: THERAPEUTIC AGENTS BASED ON MITOCHONDRIA THAT TARGET KETONE METABOLISM IN CANCER CELLS | |
| MX2017015293A (en) | COMPOSITION TO TREAT TISSULAR INJURY. | |
| CO2023016058A2 (en) | RNAi agents for inhibiting mucin 5ac (muc5ac) expression, compositions thereof and methods of use | |
| PE20121177A1 (en) | FULVESTRANT IN A DOSE OF 500 MG FOR THE TREATMENT OF ADVANCED BREAST CANCER | |
| UY29901A1 (en) | USE OF TRANSCRIPT MODIFYING AGENTS MORE CHEMOTHERAPY OR RADIOTHERAPY AGAINST CANCER | |
| AR085399A1 (en) | ANTITUMORAL COMBINATION INCLUDING CABAZITAXEL AND CISPLATINO | |
| GT201400071A (en) | THERAPEUTIC COMBINATION FOR CANCER TREATMENT | |
| MX2021011301A (en) | Tumor-selective combination therapy. | |
| Sultana et al. | The benefits of Didox in triple negative breast cancer treatment targeting mutant p53 | |
| LIU et al. | Effects of Nimesulide on Expression of Matrix Metalloproteinase-2 in Human Colonic Cancer Cell Lines | |
| AR106227A1 (en) | COMPOSITIONS AND METHODS TO INHIBIT THE GENE EXPRESSION OF THE APO APOLIPOPROTEIN GENE (a) (LPA) | |
| Michelin et al. | Non-focused and non-cancer effects induced by ionizing radiation. State of the art | |
| AR112754A1 (en) | IARN AGENTS FOR THE INHIBITION OF THE EXPRESSION OF a-ENaC AND METHODS OF USE |